InvestorsHub Logo
Followers 3
Posts 963
Boards Moderated 0
Alias Born 03/30/2021

Re: sctt post# 5298

Tuesday, 06/04/2024 5:54:49 PM

Tuesday, June 04, 2024 5:54:49 PM

Post# of 5322
Verséa Ophthalmics is building their business on the foundation of the 2 FDA cleared 510K dry eye diagnostic tests owned by AXIM. The Verséa Ophthalmics marketing agreement is also based on the right to bring the AXIM MMP-9 test through the FDA process to potentially have 3 FDA cleared tests. I also believe the tear based Point-of-Care Parkinson Disease Diagnostic test is a great 4th test to add to the TPOC family of tests.

Yes, I do believe there is still growth potential with AXIM.

However the retail investor share price is getting burned to the ground right now. Today was an exception because of the volume. The fact still remains: There is not enough cash-flow to support the business yet.


BOTTOM LINE:
AXIM and MJNA insiders have control over ALL the AXIM assets. Verséa Ophthalmics is building their business on the foundation of the exclusive marketing agreement for the AXIM Dry Eye Disease Tear based Point-of-Care tests.


MY OPINION
Personally I have been a "big" buyer below a penny in the last month or two. This is not investment advice. Penny stocks can have a high level of volatility. There is a risk of losing everything invested in AXIM. Don't invest money needed for food or rent or happiness.














Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AXIM News